MCL-1 Inhibitors | Global Pipeline

Last Update: Nov 10, 2022

MCL-1 Inhibitors

Company Candidate MOA Indications Administration Phase Clinical Trial Trial Status
Novartis & ServierS64315/MIK665MCL-1 selectiver/r DLBCL, r/r MM, r/r AML/MDS (combinations with VOB560 (BCL-2 inhibitor) or azacitidine)IVI/IINCT04629443Recruiting
AmgenAMG 176MCL-1 selectiver/r MM, r/r AML monotherapy or combinations w/ azacitidine or itraconazoleIVINCT02675452Recruiting
Prelude TherapeuticsPRT1419MCL-1 selectiver/r Hematological malignancies, r/r Solid tumors monotherapy or combination with venetoclaxIV/OralINCT05107856Recruiting
GileadGS-9716MCL-1 selectiver/r Solid tumors monotherapy or combinations (multiple)OralIa/IbNCT05006794Recruiting
Anji PharmaceuticalsANJ810MCL-1 selective--Preclin--
Captor TherapeuticsCPT-6281MCL-1 molecular glue degrader-Preclin--

Discontinued Programs

Company Candidate MOA Indications Administration Phase Clinical Trial Trial Status
AstraZenecaAZD5991MCL-1 selectiver/r AML +- VenetoclaxIVI/IINCT03218683Terminated
AmgenAMG 397MCL-1 inhibitorAML, MDS, lymphomaORALINCT03465540Terminated
AbbVIeABBV-467MCL-1 selectiveMMIVINCT04178902Terminated
Ascentage PharmaAS00491 MCL1-selective--Preclin--
Ascentage PharmaAPG-3526MCL1-selective--Preclin--